See more : Beijing Jingneng Clean Energy Co., Limited (0579.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Ambrx Biopharma Inc. (AMAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ambrx Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Xiaomi Corporation (3CP.F) Income Statement Analysis – Financial Results
- Summit Midstream Partners, LP (SMLP) Income Statement Analysis – Financial Results
- Orian Sh.M. Ltd. (ORIN.TA) Income Statement Analysis – Financial Results
- Hangjin Technology Co., Ltd. (000818.SZ) Income Statement Analysis – Financial Results
- Huarui Electrical Appliance Co.,Ltd. (300626.SZ) Income Statement Analysis – Financial Results
Ambrx Biopharma Inc. (AMAM)
About Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 7.40M | 7.46M | 13.67M | 10.31M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.40M | 7.46M | 13.67M | 10.31M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 53.31M | 54.81M | 20.43M | 26.38M |
| General & Administrative | 20.33M | 17.07M | 6.35M | 6.40M |
| Selling & Marketing | 2.73M | 0.00 | 0.00 | 0.00 |
| SG&A | 23.05M | 17.07M | 6.35M | 6.40M |
| Other Expenses | -2.22M | -3.86M | -4.75M | -38.00K |
| Operating Expenses | 74.14M | 71.88M | 26.79M | 32.78M |
| Cost & Expenses | -83.83M | 71.88M | 26.79M | 32.78M |
| Interest Income | 369.00K | 0.00 | 27.00K | 195.00K |
| Interest Expense | 968.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.29M | 2.15M | 1.94M | 2.05M |
| EBITDA | -55.79M | -62.27M | -11.17M | -20.42M |
| EBITDA Ratio | -753.69% | -835.28% | -81.72% | -198.03% |
| Operating Income | -57.08M | -64.42M | -13.12M | -22.47M |
| Operating Income Ratio | -771.16% | -864.17% | -95.93% | -217.94% |
| Total Other Income/Expenses | -18.98M | -3.86M | -4.72M | 157.00K |
| Income Before Tax | -76.06M | -68.29M | -17.84M | -22.32M |
| Income Before Tax Ratio | -1,027.55% | -915.99% | -130.48% | -216.42% |
| Income Tax Expense | 1.94M | 1.00K | 1.00K | -2.00K |
| Net Income | -78.00M | -68.29M | -17.84M | -22.31M |
| Net Income Ratio | -1,053.72% | -916.00% | -130.49% | -216.40% |
| EPS | -2.02 | -3.34 | -0.47 | -0.59 |
| EPS Diluted | -2.02 | -3.34 | -0.47 | -0.59 |
| Weighted Avg Shares Out | 38.61M | 20.45M | 37.67M | 37.67M |
| Weighted Avg Shares Out (Dil) | 38.61M | 20.45M | 37.67M | 37.67M |
How to Find and Evaluate Penny Stocks For Your Portfolio
Why Is Ambrx (AMAM) Stock Up 400% Today?
Ambrx Biopharma to Host Corporate Update Conference Call
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
Ambrx Biopharma Inc. (AMAM) CEO Feng Tian on Q4 2021 Results - Earnings Call Transcript
Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022
Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?
Source: https://incomestatements.info
Category: Stock Reports